Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Pulmonology
ASCO Journal Club
Journal Club Q&A done in partnership with ASCO the Journal of Clinical Oncology
Questions discussed in this category
How are you using liquid biopsy in the routine management of your patients with metastatic NSCLC?
Are you using ctDNA blood tests for targetable mutations at the time of diagnosis, at the time of disease progression, or not at all?
2 Answers available
1265
Papers discussed in this category
JCO Precision Oncology, 2017 Sep 29
Circulating Tumor DNA in Non–Small-Cell Lung Cancer: A Primer for the Clinician
Sci Rep, 2014 Sep 09
Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis.
Medicine (Baltimore),
Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-01
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.
Related Topics in Pulmonology
Lung Cancer
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Radiation Oncology
Gynecologic Cancers
Palliation
Neuro-Oncology
Gastrointestinal Cancers
Melanoma/Skin Cancer